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Abstract Tissue factor pathway inhibitor (TFPI) is mainly
synthesized in vascular endothelial cells and exhibits a strong and
specific inhibitory activity against tissue factor-mediated blood
coagulation. In the present study, we demonstrate that human
recombinant TFPI (h-rTFPI) inhibits the growth of cultured
human umbilical vein endothelial cells (HUVECs) by inducing
apoptosis. In a growth-rate assay of HUVECs, the growth of the
cultured HUVECs is completely abolished by the addition of
1 WM h-rTFPI to the culture medium containing fetal bovine
serum (FBS), basic fibroblast growth factor, and epidermal
growth factor. In addition, h-rTFPI and h-rTFPI-C which lacks
the carboxyl-terminal basic region prevent the survival of
growth-arrested HUVECs which are starved in a medium
containing 2% FBS alone, suggesting that h-rTFPI directly
induces the death of these HUVECs. This hypothesis is
supported by the finding that h-rTFPI does not inhibit the
synthesis of DNA in HUVECs during proliferation, as shown by
a 5-bromo-2P-deoxyuridine (BrdU) incorporation assay. Further-
more, Giemsa staining and a gel electrophoretic analysis of DNA
fragmentation show that the HUVEC death mediated by
h-rTFPI has the typical characteristics of apoptosis. However,
the apoptosis in HUVECs is considerably inhibited in the
presence of 1 Wg/ml of the protein synthesis inhibitor,
cycloheximide. Therefore, the process of apoptosis triggered by
h-rTFPI is, at least in part, actively conducted by the cells.
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1. Introduction
Embryonic vascular development involves a complex series
of events during which endothelial cells di¡erentiate, prolifer-
ate, and undergo morphological organization in the context of
their surrounding tissues [1]. Two successive processes, vascu-
logenesis and angiogenesis, are thought to contribute to em-
bryonic vascular development [2,3]. Vasculogenesis is the de
novo organization of blood vessels by the in situ di¡erentia-
tion of endothelial cells from the mesoderm. Angiogenesis is
the budding and branching of vessels from pre-existing ves-
sels. Angiogenesis in adult humans accounts for the neovas-
cularization that accompanies the normal processes of ovula-
tion, placental development and wound healing, as well as
various clinically signi¢cant pathological processes such as
tumor growth and diabetic retinopathy [4,5], while vasculo-
genesis appears to be a mechanism unique to embryonic de-
velopment. The basic mechanisms underlying vasculogenesis
and angiogenesis have been studied, and several factors with
mitogenic activity have been identi¢ed [6^8]. However, the
degeneration and regression of blood vessels are also thought
to be equally important for the early development of the vas-
cular system [9], since the minority of blood vessels formed
during embryonic development probably persists until adult-
hood and most capillaries in the primitive vascular plexus
regress. In addition, wound capillaries regress after wound
healing. The molecular mechanisms of the regression and de-
generation of vascular endothelial cells are not yet under-
stood. We speculate that the regression of blood vessels in-
volves induced endothelial cell death or apoptosis caused by
unknown factors. In the present study, we analyze a death
factor of cultured vascular endothelial cells which might
play a positive role in enhancing the vascular degeneration
and the regression.
Tissue factor pathway inhibitor (TFPI) is a Kunitz-type
protease inhibitor which exhibits a strong and speci¢c inhib-
itory activity against the tissue factor (TF)-mediated initiation
of the blood coagulation cascade [10]. It is thought that TFPI
plays a signi¢cant role in vivo in the regulation of blood
coagulation triggered by TF expressed on vascular endothelial
cells, because TFPI is synthesized mainly in vascular endothe-
lial cells and bound to the vessel wall [11^14]. It has been
suggested that TFPI is bound to glycosaminoglycans
(GAGs) on the endothelium, and that heparin competes
with this binding [15,16]. Iversen et al. [17] recently reported
that human recombinant TFPI (h-rTFPI) binds to cultured
human umbilical vein endothelial cells (HUVECs) with a dis-
sociation constant (Kd) of 0.164 WM and that the binding does
not involve GAGs. They further revealed that other unidenti-
¢ed molecules on HUVECs are responsible for the interaction
of TFPI with HUVECs. The interaction of GAGs with TFPI
is important for enhancing the inhibitory activity of TFPI
against TF-induced coagulation [18]. We recently discovered
that the interaction of h-rTFPI with cultured human smooth
muscle cells (hSMCs), mediated via the carboxyl-terminal re-
gion, is responsible for the anti-proliferative action of h-rTFPI
[19]. Therefore, it seems likely that h-rTFPI bound to endo-
thelial cells might have some other function besides as a pro-
tease inhibitor. However, it is unknown whether TFPI has a
direct action on vascular endothelial cells.
The aim of the present study was to investigate the e¡ect of
h-rTFPI on the growth of vascular endothelial cells in a cul-
ture. We found that h-rTFPI completely inhibited the growth
of HUVECs and that its action was dependent on the induc-
tion of cell death, showing the typical characteristics of apop-
tosis but not necrosis. These results suggest that TFPI plays a
signi¢cant role in regulating the development of the vascular
system and in enhancing the degeneration and regression
mediated via the induction of apoptosis in vascular endothe-
lial cells.
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2. Materials and methods
2.1. Materials
The h-rTFPI was isolated from the culture medium of transformed
chinese hamster ovary (CHO) cells with human TFPI cDNA by im-
munoa⁄nity chromatography using its monoclonal antibody
(HTFPIK-9)-conjugated Cellulo¢ne (Seikagaku Co., Tokyo, Japan),
as described [20]. For the separation of h-rTFPI from h-rTFPI-C,
which lacks the carboxyl-terminal basic region in TFPI, we performed
an a⁄nity chromatography on a heparin-Sepharose CL-6B (Pharma-
cia-LKB Biotechnology, Uppsala, Sweden) column (2.7U8.8 cm). A
chemical analysis of the isolated materials showed that h-rTFPI was a
full-length form, whereas h-rTFPI-C ended at Lys249 [21]. The h-
rTFPI concentration was determined by measuring the inhibition of
human factor Xa activity after the incubation of factor Xa with seri-
ally diluted h-rTFPI [22]. A synthetic peptide corresponding to Lys254-
Met276 in TFPI was purchased from Sawady Biotechnology Co. (To-
kyo, Japan). The concentration of the peptide was determined by an
amino acid analysis. The monoclonal antibody (HTFPIK-9) against
human TFPI was puri¢ed by the previously described methods [23].
The following materials were obtained from the listed companies:
crystallized bovine serum albumin (BSA), cycloheximide (Sigma
Chemical Co., St. Louis, MO, USA), 0.025% trypsin containing
0.01% EDTA (trypsin/EDTA) (Kurabo Co., Osaka, Japan), and
0.4% trypan blue (Flow Laboratories, Irvine, Scotland). All other
chemicals, reagent grade or better, were from Wako Pure Chemical
Industries (Osaka, Japan) or Nacalai Tesque (Kyoto, Japan).
2.2. HUVEC cultures
The HUVECs were purchased from Kurabo. The cells were isolated
from human umbilical cord veins and identi¢ed by an immunological
analysis of von Willebrand factor. The HUVECs were cultured in the
growth medium HuMedia-EG2 (Kurabo), and grown at 37‡C in a
humidi¢ed atmosphere at 5% of CO2 in air. The HuMedia-EG2 me-
dium consisted of the base medium (HuMedia-EB2) supplemented
with 2% fetal bovine serum (FBS), 10 ng/ml recombinant epidermal
growth factor (rEGF), 5 ng/ml recombinant basic ¢broblast growth
factor (r-bFGF), 10 Wg/ml heparin, and 1 Wg/ml hydrocortisone. Con-
£uent adherent HUVECs were detached from 75 cm2 £asks (Iwaki,
Chiba, Japan) by exposure to a trypsin/EDTA solution at room tem-
perature, and the detached cells (routinely over 98% viable as assessed
by trypan blue assay) were then suspended in the HuMedia-EG2
medium. HUVECs were routinely used from the fourth to the ¢fth
passage.
2.3. Assays of HUVEC growth
Three hundred microliters of HUVEC suspension was plated in a
48-well plate (Iwaki) at 2.5U103 cells per well and cultured in Hu-
Media-EG2 medium. At day 2, the culture medium was changed to a
fresh HuMedia-EG2 medium containing various concentrations of h-
rTFPI. The medium was changed thereafter every 2 days. For the
growth-rate determination, cells were trypsinized with 100 Wl of a
trypsin/EDTA solution and resuspended in 4.7 ml of ISOTON-II
(Japan Scienti¢c Instruments Co., Osaka) following the neutralization
of trypsin by 200 Wl of FBS (Kurabo). Then, the number of cells in
suspension was determined by a Coulter counter (Japan Scienti¢c
Instruments).
2.4. Preparation of growth-arrested HUVECs
For the preparation of growth-arrested HUVECs, HUVECs were
starved in a growth factor-depleted medium. In brief, HUVECs were
seeded at 12U103 cells per well in a 48-well plate and cultured in
growth factor-depleted medium. After 2 days, the medium was re-
placed by fresh growth factor-depleted medium, and the HUVECs
were further cultured for 2 days. The growth factor-depleted medium
contained HuMedia-EB2 and 2% FBS, but not rEGF or r-bFGF. To
determine whether h-rTFPI would induce the death of HUVECs,
adherent cells were trypsinized and counted in a Coulter counter at
2 days after the cultivation in the presence of varying concentrations
of h-rTFPI.
2.5. DNA synthesis assays
To test the e¡ect of h-rTFPI on the DNA synthesis in HUVECs, we
performed a 5-bromo-2P-deoxyuridine (BrdU) incorporation assay
with a commercial quanti¢cation kit (Boehringer Mannheim, Tokyo)
according to the manufacturer’s protocol. Brie£y, 100 Wl of HUVEC
suspension was plated in a 96-well plate (Becton Dickinson, Lincoln
Park, NJ, USA) at 5U103 cells per well and allowed to attach to the
culture plate. At 4 h, the culture medium was changed to a fresh
HuMedia-EG2 medium containing h-rTFPI (1 WM), and the HU-
VECs were further cultured for 24 h. BrdU was added to the culture
medium at 0, 6, 12, and 18 h after an addition of h-rTFPI, and
incubated for 6 h for labeling the HUVECs. After labeling, the
BrdU-treated cells were ¢xed and the DNA was denatured. The
BrdU incorporated into newly synthesized cellular DNA was reacted
with a peroxidase-conjugated anti-BrdU antibody, and the immune
complexes were quanti¢ed by the subsequent substrate reaction. The
amount of reaction product was determined by measuring the absorb-
ance at 450 nm using a plate reader (THERMOmax, Molecular De-
vices Co., Menlo Park, CA, USA). The absorbance value was directly
correlated to the amount of DNA synthesis and to the number of
proliferative cells.
2.6. Estimation of apoptotic HUVECs
For investigating whether h-rTFPI triggers apoptosis in HUVECs,
we performed an estimation of apoptotic HUVECs by using the
Giemsa staining method. To obtain dead cells, adherent HUVECs
were incubated with h-rTFPI in a HuMedia-EG2 medium for
2 days, and then £oating cells in the medium were collected. These
cells were centrifuged and used to estimate the number of apoptotic
cells. To assess the cells’ viability, 1 volume of trypan blue was added
to 1 volume of the cells, and the viable cells were then counted in a
hemocytometer. The dead cells were stained with Giemsa (Merck,
Darmstadt, Germany), and were examined over 1U105 cells per slide
by oil immersion light microscopy at a ¢nal magni¢cation of 250.
Apoptotic cells were identi¢ed according to the following criteria
[24] : condensed and fragmented nuclei, and decrease in cell size.
2.7. Detection of DNA fragmentation
For further investigating HUVEC apoptosis induced by h-rTFPI,
fragmented and intact DNA in dead cells was evaluated by means of
an apoptosis ladder detection kit from Wako Pure Chemical Indus-
tries according to the manufacturer’s protocol. Brie£y, after the HU-
VECs £oating in medium (8U105) were collected and centrifuged, the
DNA in the cells was extracted. The DNA samples were combined
with loading bu¡er and electrophoresed in a 1.5% agarose gel. The
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Fig. 1. Inhibition of HUVEC growth by h-rTFPI. Cells were seeded
in 48-well plates at 2.5U103 cells per well, and the culture medium
was changed at 48 h to a fresh growth medium containing various
concentrations of h-rTFPI. The medium was changed every 2 days
thereafter. For the growth rate determination, cells were detached
from 4 wells and counted in a Coulter counter. Each point indicates
the mean cell number þ S.D. (n = 4). The data for each culture day
represent a signi¢cant di¡erence from the data for no h-rTFPI by
unpaired Student’s t-test; *P6 0.05, **P6 0.01. (a) No h-rTFPI;
(O) 0.13 WM h-rTFPI; (E) 0.25 WM h-rTFPI; (b) 0.5 WM h-rTFPI;
(R) 1 WM h-rTFPI; (F) 2 WM h-rTFPI.
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DNA was visualized by UV examination and photographed with a
Polaroid camera. For comparison, adherent cells cultured in the ab-
sence of h-rTFPI were trypsinized, and the DNA in these cells was
also analyzed.
2.8. Statistics
Statistical analysis was performed with the unpaired Student’s t-
test. In this test, data are considered signi¢cant if P6 0.05.
3. Results
3.1. Inhibition of the growth of HUVECs by h-rTFPI
We investigated the e¡ect of varying concentrations of h-
rTFPI on the growth of cultured HUVECs. As shown in Fig.
1, the growth of HUVECs cultured in growth medium was
signi¢cantly inhibited by the addition of h-rTFPI in a dose-
dependent fashion at day 4 and 6, and 1 WM h-rTFPI com-
pletely abolished the growth of HUVECs in culture. We also
observed morphological changes in h-rTFPI-treated HU-
VECs, wherein cells rounded up and £oated away into the
medium. When we compared the number of cells treated by
2 WM h-rTFPI with that before the addition of h-rTFPI (cor-
responding to the number of cells at day 2), it was clear that
the number of h-rTFPI-treated cells was much lower than that
of the non-treated cells, suggesting that h-rTFPI induced cell
death. Similar tests of h-rTFPI on the growth of bovine aortic
endothelial cells also showed a signi¢cant inhibitory e¡ect,
while in human ¢broblasts, h-rTFPI had no signi¢cant e¡ect
(data not shown).
3.2. The e¡ect of h-rTFPI on the survival of growth-arrested
HUVECs
We also examined the e¡ect of h-rTFPI on the survival of
growth-arrested HUVECs in order to clarify whether the in-
hibitory e¡ect of h-rTFPI on HUVEC growth contributed to
the inhibition of the proliferation of HUVECs by exogenously
added growth factors such as bFGF and EGF. In this experi-
ment, we used growth-arrested HUVECs which were starved
in HuMedia-EB2 supplemented with 2% FBS. As a result, the
number of adherent cells (corresponding to survived cells) was
signi¢cantly decreased in a dose-dependent manner by the
addition of h-rTFPI to starved HUVECs, indicating that the
survival of the growth-arrested HUVECs was inhibited by
h-rTFPI (Fig. 2). We thus noted that it was possible that
h-rTFPI induced the death of the HUVECs and that the
h-rTFPI was mainly responsible for the inhibitory e¡ect on
HUVEC growth. This possibility was further supported by
the BrdU incorporation assay ¢nding that h-rTFPI did not
inhibit the synthesis of DNA in HUVECs during prolifera-
tion, indicating that h-rTFPI has no direct anti-mitogenic ac-
tivity toward the HUVECs stimulated by growth factors (Fig.
3). To evaluate the functional domain in h-rTFPI, we tested
the e¡ect of h-rTFPI-C and the Lys254-Met276 peptide on the
survival of HUVECs. As shown in Fig. 4, h-rTFPI-C signi¢-
cantly inhibited the survival of HUVECs, whereas the Lys254-
Met276 peptide did not.
3.3. h-rTFPI-dependent induction of apoptotic cell death
The Giemsa staining and gel electrophoretic analysis of
DNA fragmentation were used to determine whether h-rTFPI
triggers apoptosis in HUVECs. These morphological and bio-
chemical analyses demonstrated the typical characteristics of
apoptosis in the HUVECs incubated with 2 WM h-rTFPI. As
shown in Fig. 5A, the HUVECs £oating in the medium after
treatment by h-rTFPI showed highly condensed and frag-
mented nuclei, and a decrease in cell size. The electrophoretic
analysis demonstrated the characteristic pattern of fragmenta-
tion of DNA in multiples of 180^200 bp (Fig. 5B). These
results suggest that the HUVEC death induced by h-rTFPI
was apoptosis. Apoptosis is an active process that requires
macromolecular synthesis, and the apoptosis in vascular en-
dothelial cells is inhibited by a protein synthesis inhibitor [25].
When we cultured HUVECs in the simultaneous presence of
h-rTFPI and cycloheximide (1 Wg/ml), cycloheximide aug-
mented the survival of cells at day 2 (Table 1) and the process
of apoptosis triggered by h-rTFPI was prevented to a consid-
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Fig. 2. The e¡ect of h-rTFPI on the survival of growth-arrested
HUVECs. HUVECs were seeded at 12U103 cells per well in a 48-
well plate and cultured in growth factor-depleted medium which
contained HuMedia-EB2 and 2% FBS. After 2 days, the medium
was replaced by fresh growth factor-depleted medium supplemented
with varying concentrations of h-rTFPI, and the HUVECs were fur-
ther cultured in the presence of h-rTFPI for 2 days. After cultiva-
tion, adherent cells were trypsinized and counted in a Coulter coun-
ter. Each bar indicates the mean of the survived cell number þ S.D.
(n = 4). *P6 0.05 or **P6 0.01 vs. no h-rTFPI.
Fig. 3. No e¡ect of h-rTFPI on DNA synthesis in HUVECs. To
test the e¡ect of h-rTFPI on DNA synthesis in HUVECs, we per-
formed a BrdU assay as described under Section 2. The absorbance
value at 450 nm directly correlated to the amount of DNA synthe-
sis. Each point indicates the mean absorbance þ S.D. (n = 6). Open
bars, no h-rTFPI; solid bars, 1 WM h-rTFPI.
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erable degree, suggesting that the apoptosis was, at least in
part, actively conducted by the cells. Thus, the treatment of
HUVECs with h-rTFPI resulted in an active process of cell
death with the morphological and biochemical characteristics
of apoptosis.
4. Discussion
Apoptosis or programmed cell death is a form of cell death
wherein the cells participate in their own demise; this process
is morphologically and biochemically di¡erent from necrosis,
and occurs under physiologic and pathophysiologic conditions
[26]. Brie£y, the areas in which apoptosis plays an important
role can be divided as follows: (1) during embryological and
fetal development (e.g. the cavitation of the embryo and limb
bud development) [27]; (2) in normal homeostasis (e.g. the
turnover of intestinal epithelial cells) [27] ; and (3) in disease
states [26]. Various factors or stimuli that induce apoptosis in
vascular endothelial cells have been identi¢ed, e.g. tumor ne-
crosis factor-K (TNF-K) [28,29], and high glucose concentra-
tion [30]. The deprivation of a growth factor such as bFGF
also induces apoptosis in endothelial cells [31,32]. The apop-
tosis of endothelial cells induced by these factors is generally
thought to contribute to vascular pathology, including athe-
rosclerosis and in£ammation [28,33]. Bombeli et al. [34] have
shown that apoptotic endothelial cells become procoagulant,
suggesting that the apoptotic cells may play a role in the
development of thrombotic events.
Endothelial cell apoptosis is also physiologically signi¢cant
in normal tissue homeostasis and embryological development
[9,29]. However, the molecular mechanism of apoptosis re-
mains poorly understood. In the present study, we investi-
gated a death factor in vascular endothelial cells which may
play a positive role in enhancing vascular degeneration and
regression. We observed that this factor, TFPI, was di¡erent
from the above apoptosis-inducing factors. Our experiments
showed that h-rTFPI inhibits the growth of cultured HU-
VECs and that its action contributed to the apoptotic cell
death which is mainly involved in de novo protein synthesis.
Iversen et al. [17] recently demonstrated that h-rTFPI binds to
cultured HUVECs with Kd value of 0.164 WM. When the
concentrations of h-rTFPI used in this study were compared
with the Kd value reported by Iversen et al., it was found that
the concentrations of h-rTFPI required for apoptotic action
are rather close to the Kd value (0.164 WM vs. 0.13 WM^2
WM). These results lead to our speculation that vascular en-
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Fig. 4. The e¡ect of h-rTFPI-C and the Lys254-Met276 peptide on the survival of HUVECs. The e¡ect of h-rTFPI-C and the Lys254-Met276 pep-
tide (inset) on the survival of HUVECs were investigated by the methods described in the legend to Fig. 2. Each point indicates the mean of
the survived cell number þ S.D. (n = 4). *P6 0.05 or **P6 0.01 vs. no h-rTFPI-C.
Table 1
E¡ect of cycloheximide on the cell death induced by h-rTFPI
h-rTFPI (WM) Cycloheximide Percent of viable cells (%)
0 3 100.0 þ 9.0
+ 100.0 þ 3.7
1 3 42.4 þ 5.2
+ 77.4 þ 8.9**
2 3 33.4 þ 10.2
+ 65.8 þ 3.8**
Growth-arrested HUVECs were prepared in growth factor-depleted
medium and cultured in the presence of h-rTFPI and/or cyclohexi-
mide for 2 days, as detailed in Fig. 2. Cycloheximide was used at 1 Wg/
ml. After cultivation, adherent cells were trypsinized and counted in a
Coulter counter. Each value indicates the percent of survived
cells þ S.D. (n = 4).
**P6 0.01 vs. no cycloheximide. +, presence; 3, absence.
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dothelial cells in which apoptosis is triggered by TFPI, are
phagocytosed into neighboring phagocytic cells and then de-
graded, ¢nally resulting in the elimination of the dying cells
without the induction of the in£ammatory and hypercoagula-
tion processes, because TFPI prevents the hypercoagulation
and in£ammation [35]. We also discovered that h-rTFPI has
an anti-proliferative e¡ect on hSMCs [19]. Taken together,
these ¢ndings suggest that TFPI plays a physiologically sig-
ni¢cant role in the establishment of the vascular system during
embryological development and angiogenesis by inducing the
apoptosis of vascular endothelial cells and by regulating
hSMC growth.
On the basis of the present studies, h-rTFPI may transmit
the direct death signal to cultured HUVECs, although neither
the membrane receptor nor signalling system has been identi-
¢ed. TFPI is a Kunitz-type protease inhibitor which exhibits a
strong and speci¢c inhibitory activity against the coagulation
factors VIIa-TF complex and Xa. However, it seems unlikely
that the inhibitory activity of h-rTFPI is required for inducing
the apoptosis in HUVECs, because the inhibitory activity of
h-rTFPI was abolished after reduction and alkylation of h-
rTFPI, but not the apoptotic action (data not shown). In
addition, TFPI is a heparin-binding protein which binds via
the carboxyl-terminal and third Kunitz domain [16,20].
Among the heparin-binding proteins, the signi¢cance of the
anti-proliferative e¡ect of platelet factor-4 on endothelial cells
has been well established [36,37]. The e¡ect is thought to be
mainly attributable to the competition with the heparin-bind-
ing growth factors such as FGFs for cell surface GAGs. How-
ever, it seems unlikely that h-rTFPI can induce the apoptosis
in HUVECs mediated by the interaction of h-rTFPI with
GAGs, because the apoptotic action of h-rTFPI is observed
in the presence of a high concentration of heparin (Fig. 1),
and the Lys254-Met276 peptide which contains GAG-binding
region does not prevent the survival of HUVECs (Fig. 4).
Therefore, it is possible that receptors other than GAGs on
endothelial cells are involved in the apoptotic action of h-
rTFPI, suggesting that the mechanism for endothelial cell
apoptosis induced by TFPI is di¡erent from that for the
anti-proliferative e¡ect on hSMCs.
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Fig. 5. Estimation of apoptotic HUVECs by using Giemsa staining
and a gel electrophoretic analysis of DNA fragmentation. To deter-
mine whether h-rTFPI induces apoptosis in HUVECs, we performed
the Giemsa staining and gel electrophoretic analysis of DNA frag-
mentation described in Section 2. A: Apoptotic HUVECs stained
with Giemsa. B: Gel electrophoretic pattern of DNA fragmentation.
Lane 1, DNA from living cells (adherent cells) ; lane 2, DNA from
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ment; lane 3, molecular weight markers. The molecular weights are
expressed in terms of base pairs.
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